Strategies for Biomarker Evaluation in Patients With NSCLC: From EGFR to PD-L1
Strategies for Biomarker Evaluation in Patients With NSCLC:
From EGFR to PD-L1
Harborside Medical Education
Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners’ knowledge, competence and performance in both community and academic practice settings.
Release date: November 13, 2018
Expiration date: November 13, 2019
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Estimated time to complete activity: 0.5 hour
The ASCO Post
94 North Woodhull Road
Huntington, NY 11743
This activity is supported by educational grants from Celgene Corporation, Merck Sharp & Dohme Corp., and Takeda Oncology.
The activity’s target audience is medical and hematologic oncologists, nurse practitioners, physician assistants, oncology pharmacists, clinical nurse specialists, and other clinicians who care for people with cancer.
After completing this educational activity, participants should be able to:
- Evaluate best practices and interpret the clinical significance of emerging data regarding the role of biomarkers for diagnosing and treating patients with NSCLC
- Plan strategies to incorporate best practices and emerging data regarding biomarkers into practice
- Use biomarkers effectively to guide treatment selection
Alice Tsang Shaw, MD, PhD
Director, Center for Thoracic Cancers, Massachusetts General Hospital;
Professor of Medicine, Harvard Medical School
Lecia Sequist, MD, MPH
Landry Family Associate Professor of Medicine, Harvard Medical School;
Director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital Cancer Center
Justin Gainor, MD
Assistant Professor, Center for Thoracic Cancers, Harvard Medical School
Massachusetts General Hospital
Statement of Credit—Participants who successfully complete this activity (including the submission of the posttest and evaluation form) will receive a statement of credit.
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Harborside Medical Education. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. A maximum of 0.5 contact hours may be earned for successful completion of this activity.
Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 0.5 contact hours.
Pharmacists. The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-18-214-H01-P. This program is designated for up to 0.5 contact hours (0.5 CEUs) of continuing pharmacy education credit.
All individuals in positions to control the content of this activity (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the Annenberg Center for Health Sciences at Eisenhower policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Dr. Shaw has received research support from Genentech/Roche, Novartis, and Pfizer; and served as consultant for Ariad, Blueprint Medicine, Chugai, Genentech/Roche, Ignyta, KSQ, Loxo Oncology, Natera, Novartis, Pfizer, and Takeda.
Dr. Sequist has received research support from AstraZeneca, Boehringer Ingelheim, Genentech, Merrimack, and Novartis; and has served as consultant for AstraZeneca, Blueprint Medicines, Genentech, and Merrimack.
Dr. Gainor has served as consultant for Agios, Amgen, Ariad/Takeda, Array, Bristol-Myers Squibb, Novartis, Oncorus, Pfizer, Regeneron, and Roche.
Annenberg Center for Health Sciences at Eisenhower
Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Moshe C. Ornstein, MD, MA, Cleveland Clinic Taussig Cancer Institute, has served as a consultant and speaker for Eisai, Pfizer, and Exelixis.
Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has no potential conflicts of interest to disclose.
Harborside and Harborside Medical Education staff have no potential conflicts of interest to disclose.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population. The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
Learners must complete the learning assessment and evaluation.
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 75% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
- 0.50 ACPE
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Attendance
- 0.50 CA-BRN
- 0.50 ANCC